SCHEMBL16445772

SCHEMBL16445772

CN(c1nc(Nc2ccc(CC(=O)O)cc2)ncc1Cl)C1CCCO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 7/20 0.44
FGFR1 P11362 2/20 0.42
EGFR P00533 1/20 0.42
FGFR2 P21802 1/20 0.42
FGFR4 P22455 1/20 0.42
FGFR3 P22607 1/20 0.42
AURKA O14965 1/20 0.42
LCK P06239 3/20 0.41
JAK3 P52333 2/20 0.41
PDE4B Q07343 4/20 0.41
PDE4D Q08499 3/20 0.41
JAK2 O60674 5/20 0.40
CHEK1 O14757 1/20 0.40
ABL1 P00519 1/20 0.40
ROS1 P08922 1/20 0.40
SRC P12931 1/20 0.40
TYK2 P29597 1/20 0.40
ALK Q9UM73 1/20 0.40
JAK1 P23458 4/20 0.40
BTK Q06187 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16445767 1.00 TNK2 (0.44) TNK2FGFR1EGFRFGFR2FGFR4
SCHEMBL16446055 1.00 TNK2 (0.44) TNK2FGFR1EGFRFGFR2FGFR4
SCHEMBL16446431 0.91 TNK2 (0.42) TNK2FGFR1EGFRAURKALCK
SCHEMBL16445556 0.91 TNK2 (0.42) TNK2FGFR1EGFRAURKALCK
SCHEMBL16445938 0.91 TNK2 (0.42) TNK2FGFR1EGFRAURKALCK
SCHEMBL16445393 0.89 FGFR1 (0.45) TNK2FGFR1EGFRLCKJAK3
SCHEMBL16445776 0.89 FGFR1 (0.45) TNK2FGFR1EGFRLCKJAK3
SCHEMBL16445913 0.89 FGFR1 (0.45) TNK2FGFR1EGFRLCKJAK3
SCHEMBL16445721 0.89 TNK2 (0.44) TNK2LCKJAK3PDE4BPDE4D
SCHEMBL16445571 0.85 AURKA (0.48) TNK2FGFR1AURKALCKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017478-B2 Inhibitors of ACK1/TNK2 tyrosine kinase H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2018-07-10 US disclosed
US-20180155297-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2018-06-07 US disclosed
US-9850216-B2 Inhibitors of ACK1/TNK2 tyrosine kinase H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2017-12-26 US disclosed
US-20160176826-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-06-23 US disclosed
EP-3030241-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) 2016-06-15 EP disclosed
WO-2015021149-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2015-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176826-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE TNK1, TNNI3K, TNK2 TNK2 3/4885FGFR1 1010/4885EGFR 550/4885
US-10017478-B2 Inhibitors of ACK1/TNK2 tyrosine kinase TNK1, TNNI3K, TNK2 TNK2 3/4885FGFR1 1010/4885EGFR 550/4885
US-20180155297-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE TNK1, TNNI3K, TNK2 TNK2 3/4885FGFR1 1010/4885EGFR 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.